Nonreplicative recombinant HIV-1-derived lentiviral vectors (LV) are increasingly used in gene therapy of various genetic diseases, infectious diseases, and cancer. Before they are used in humans, preparations of LV must undergo extensive quality control testing. In particular, testing of LV must demonstrate the absence of replication-competent lentiviruses (RCL) with suitable methods, on representative fractions of vector batches. Current methods based on cell culture are challenging because high titers of vector batches translate into high volumes of cell culture to be tested in RCL assays. As vector batch size and titers are continuously increasing because of the improvement of production and purification methods, it became necessary for us to modify the current RCL assay based on the detection of p24 in cultures of indicator cells. Here, we propose a practical optimization of this method using a pairwise pooling strategy enabling easier testing of higher vector inoculum volumes. These modifications significantly decrease material handling and operator time, leading to a cost-effective method, while maintaining optimal sensibility of the RCL testing. This optimized ''RCL-pooling assay'' ameliorates the feasibility of the quality control of large-scale batches of clinical-grade LV while maintaining the same sensitivity.
INTRODUCTION
RECOMBINANT GENE TRANSFER VECTORS derived from lentiviruses are useful laboratory tools and are increasingly used in medical applications with promising results. Nonreplicative lentiviral vectors (LV) are now tested in several early phase clinical trials to treat a variety of monogenic diseases, including neurodegenerative disorders, 1,2 ocular diseases, 3 hemoglobinopathies, 4 primary immune deficiencies, [5] [6] [7] and also to treat infectious diseases 8 or cancers. 9 Based on successes obtained in these clinical applications, it is likely that clinical gene therapy projects based on LV will continue to develop further. When using nonreplicative LV in humans, it is mandatory to ensure that replicationcompetent lentiviruses (RCL) are not present in the viral stock, as required by the European Pharmacopeia and by the FDA. 10, 11 RCL can potentially generate new infectious agents with a risk of pathogenicity, genotoxicity, or transmission. Thus, before nonreplicative LV can be released for human use, the absence of RCL must be demonstrated by adequate tests.
The majority of the LV used in the clinic are advanced third-generation nonreplicative rHIV-1-derived LV pseudotyped with the vesicular stomatitis virus G glycoprotein (VSVg). Such vectors have been extensively engineered to reduce the risk of occurrence of RCL. 12 These LV are produced from split genome systems with heterologous viral sequences and minimized homologies to limit possibilities of recombination between constructs and with viruses. 13 The self-inactivating design of the vector also prevents the expression of a proviral transcript beyond producer cells. 14 The producer cells and culture medium components undergo viral safety testing to demonstrate the absence of adventitious viruses, in particular the absence of retroviruses that could be mobilized during production. The probability that RCLs are present in the stocks of LV produced is therefore extremely low and has never been observed up to now. 15 Yet, RCL testing is mandatory on a representative fraction of LV batch, such as 5% of the bulk product. 10, 11 Currently, at a scale of 20-100 liters of harvested bulk production for clinical LV batches, approximately 200-300 ml of final product is obtained with titers greater than 2 · 10 8 infectious units/ml; therefore, approximately 10-15 ml and greater than 2 · 10 9 infectious units have to be tested for RCL. 5, 6, 16, 17 Different methods exist to evaluate the presence of RCL that must take into account the specific vector design and target cell specificity. 18, 19 The typical assays that have been developed to test VSVg-pseudotyped rHIV-LV include cell culturebased methods, 20, 21 which can be associated to PCR-based detection of amplifications of the encapsidation sequence or the envelop gene (Psi-Gag or VSV-G) or product-enhanced reverse transcriptase assay (PERT). 22 Despite their high sensitivity and rapidity, PCR-based methods have been shown to produce false-positive results, 19, 21, 22 and cellculture based assays still remain the standard method in spite of their labor-intensive practice. Cell culture assays require preliminary verification that the tested vector does not have toxicity on the target cells and generally low multiplicity of infection (MOI 5) is used, as some LV can reduce the target cells' proliferation. 21 To test for the absence of RCL in clinical-grade LV, we and several other groups are currently using the cell culture-based assay developed by Escarpe et al. 20 This assay is based on the amplification of the putative RCL after infection of a highly permissive C8166-45 T-cell line. Then, by subsequently culturing these cells over several passages, it is possible to detect a single infection event by observing HIV-1 p24 protein levels increasing over the background level. This long culture period allows the dilution of p24 protein contents carried by the viral vector inoculums, the dilution of potential contaminating nucleic acid sequences used to generate the vector, and the reduction of false-positive test results. This assay is widely used and has been employed to control several batches of clinical-grade LV tested in humans. 1, 2, 5, 6 Genethon has manufactured several lots of clinical-grade LV for the ex vivo gene therapy of primary immune deficiencies such as WiskottAldrich syndrome (WAS) and X-linked chronic granulomatous disease (X-CGD). Our current standard operating procedures for quality control testing consist of infecting the C8166-45 indicator cell line 23 with the test LV at a low MOI of 5 and amplifying all of the cell culture supernatants generated over a period of up to 6 passages and measuring p24 contents in all these samples. Considering that we routinely generate over 1.5 · 10 10 infectious units to test per clinical batch, this requires the handling of up to 60 flasks of C8166-45 cell culture over 29 days. Such an approach is becoming increasingly difficult to implement, prompting us to modify the procedure to reduce the culture size while maintaining the same sensitivity of the assay.
We herein propose an optimized RCL test protocol, called RCL-pooling assay, in which the transduction of indicators cells is performed at a high MOI and flasks are pooled at each passage after the period of amplification. We have used several lots of WAS and X-CGD LV to assess the feasibility of the modification and to verify a lack of impact on cell viability and test sensitivity. With these practical improvements, material handling and operator time is significantly reduced while the sensitivity of the assay remains the same.
MATERIALS AND METHODS

Recombinant HIV-1-derived vectors
Four batches of rHIV-1-derived LV pseudotyped with VSVg were produced at large scale (50 liters) at Genethon using quadri-transfection of 293T cells in CF10 stacks followed by several steps of membrane and chromatography purification. 16 Table 1 shows the characteristics of batches tested. Two batches of WAS LV were used. The WAS LV encodes the full-length WAS cDNA under the control of the WAS gene promoter sequence and is used to treat WAS. Two batches of GP91 LV were also used. GP91 is a codon-optimized form of the CYBB cDNA described in ref. 24 The GP91 LV is used to treat the X-linked form of chronic granulomatous disease 
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(X-CGD). The GP91 LV has been produced similarly to the WAS LV. Overall, extensive quality control testing is performed on these LV batches, as reported. 5 For RCL testing of these large-scale batches, 5% of the volume of the bulk purified product was sampled.
Indicator cells
C8166-45 cells, a human T lymphocyte cell line (AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, Bethesda, MD) highly permissive for HIV-1, has been used as an indicator cell line to amplify potential RCL. 20, 21, 25 Cells were routinely cultured in IMDM medium, supplemented with 9% FCS, 0.9% penicillin-streptomycin cocktail, and 0.9· Glutamax (all culture reagents from Invitrogen-ThermoFisher Scientific, Waltham, MA). Cell viability was measured using the trypan blue counting method (Sigma Aldrich, St. Louis, MO).
HIV-1-positive control and TCID50 calculation
The reference positive control (R8.71/VSV.G) harboring both the HIV-1 and the VSVg envelope glycoproteins is produced by co-transfection of a wild-type HIV-1 proviral plasmid lacking the accessory viral genes (DvifDvprDvpuDnef) and another plasmid encoding the VSVg glycoprotein. 20 This virus is able to replicate in CD4+/CXCR4+/Dvif permissive cell lines. A permissivity test performed on C8166 cells was used to calculate the virus TCID50 (tissue culture inhibition dose 50%). Two 96-wells plates were seeded with 1 · 10 6 C1866 cells in 100 ll of media. Serial dilutions of the positive control, ranging from 0.32 to 100 fg p24/well, were tested in 16 replicates each. Four days after the infection, 25 ll of fresh medium was added to each well for feeding. After an additional 4 days (day 8), for each well of the 96-wells plates, the supernatant was frozen at less than -70°C for further p24 quantification. The TCID50 of the positive control was calculated with the Reed-Muench method 26 and was found to be 7.9, 8.8, 6.2, and 6.7 fg p24 for the 2 validation runs and the 2 test runs, respectively.
RCL p24-decay assay
The p24 decrease assay has been described in ref. 20 Briefly, cell culture flasks are seeded with 50 · 10 6 indicator cells (10 6 cells/ml) and transduced with the vector to test. A medium supplementation is performed at day 4 (+25 ml) and a first passage at day 8 (12.5 ml in 37.5 ml fresh medium). At days 11, 15, 18, 22, and 25, 1/4th dilutions are performed (10 ml in 30 ml medium) for each flask. At day 29, the final harvest, 1 ml of each flask is transferred to a new flask containing 9 ml of fresh medium until all analyses are performed as a backup. An aliquot from the supernatant at each time point was stored at -20°C for further p24 quantification and 2 pellets of 2 · 10 6 cells were also prepared and stored at -20°C. p24 quantification in the culture supernatant was performed at each time point and for all the conditions using the HIV-1 p24 ELISA kit (PerkinElmer, Akron, OH) according to manufacturer's protocol.
P24 assay acceptability criteria
In order for the vector to pass the RCL detection test, the negative control cultures must show an undetectable level of p24 across passages. The positive control cultures have to be productively infected and have to reach, on one or more time points, a p24 level of at least 500 ng/ml between day 22 and day 29. Moreover, the value of the positive control TCID50 must be £90 fg p24/TCID50, confirming that the cells are permissive to the positive control. All the cultures, transduced only with the vector to test, have to show a gradual decrease of the p24 concentrations in the culture supernatant and must be below 100 pg/ml in all the cultures at day 29. Otherwise, the assay is extended to a time point reaching a p24 concentration lower than 100 pg/ml. If p24 concentrations are not decreasing during passages, the tested vector batch will be considered positive for the presence of RCL.
Specific sequences detection
dGAG detection: Fw, 5¢-GGAGCTAGAACGAT TCGCAGTTA-3¢; Rv, 5¢-GGTTGTAGCTGTCCCA GTATTTGTC-3¢; probe, 5¢-FAM-ACAGCCTTCTG ATGTTTCTAACAGGCCAGG-TAMRA-3¢. wtGAG detection: Fw, 5¢-GATTGTACTGAGAGACAGGC TAATTTTTT-3¢; Rv, 5¢-CCCCAAACCTGAAGCTC TCTT-3¢; probe, 5¢-FAM-TTCTTCAGAGCAGACC AGAGCCAACAGC-TAMRA-3¢. VSVg detection: Fw, 5¢-TTCTTCAGAGCAGACCAGAGCCAACAG C-3¢; RV, 5¢-GAGGAGTCACCTGGACAATCACT-3¢; probe, 5¢-FAM-AGGAACTTGGCTGAATCCAG GCTTCC-TAMRA-3¢. Albumin detection: Fw, 5¢-GCTGTCATCTCTTGTGGGCTGT-3¢; Rv, 5¢-ACTC ATGGGAGCTGCTGGTTC-3¢; probe, 5¢-VIC-CCC ACACAAATCT-MGB-3¢. Oligonucleotides were obtained from Applied Biosystem (ThermoFisher Scientific) and the qPCR mix from ABgene (Absolute QPCR Rox Mix) (ThermoFisher Scientific). Amplification was performed in triplicates each from 100 ng of gDNA using 95°C for 15 min initial denaturation followed by 45 cycles of 95°C for 15 sec and 60°C for 1 min. Three control plasmids were used as standard for quantification: pRRLcpptPGKGFP-WPRE-Alb contains dGAG and hAlb sequences, pHDMH-gpm2 contains wtGAG sequence, and pMD.G contains the VSV sequence. Standard curves were built with a copy number ranging from 20 to 10 6 copies of each plasmid. The acceptable qPCR efficiency must range between 90% and 110%, R 2 has to be greater than 0.99, the limit of quantitation has to be lower than 100 copies, and both wtGAG and VSVg amplification must remain low or undetectable over time in tested vectors.
RESULTS AND DISCUSSION
Simulated-pooling assay design
In order to obtain a substantial reduction in material handling during the RCL assay, we herein propose an ''RCL-pooling assay'' strategy based on successive pairwise pooling of cell culture flasks (Fig. 1) . To validate this strategy, we compared the detection of positive control RCLs in an LV preparation using the classical method to a simulated pooling method designed to mimic pairwise pooling while maintaining the number of original flasks (Fig. 2 ). An end-point concordance analysis will verify the RCL positivity and negativity outcome for each flask tested with the two methods. Starting from passage 2, each original infected flask was split and analyzed by both methods in parallel. In the simulated-pooling method, cells were diluted with cells originating from a side cell culture and transduced with the same LV preparation at the same MOI but without the positive control virus (Fig. 2, blue flask) . The amplification period of 8 days enables the amplification of any potential RCL and maintains the sensitivity of the assay. Indeed a false-negative result could be obtained by over diluting cells during this early step of the assay. For each passage up to passage 6, an amount of 5 ml of parent flask was mixed with 5 ml of cells from the side culture and 30 ml of fresh medium, whereas for the standard method, a classical 1/4th dilution (10 ml in 30 ml fresh medium) was performed for each flask. Finally, 1 ml of each flask was transferred to a new T75 flask containing 9 ml of fresh medium and maintained in culture until p24 quantification was complete for all samples. Control flasks were maintained either by standard passage or by pooling with side culture cells. Two preparations of LV were used for the validation of the pooling strategy with the simulated-pooling design. We also investigated the influence of high MOI on assay sensitivity by transducing indicator cells at MOI 10 and 20 in the 2 validation runs. After the validation runs, two other clinical-grade LV batches were analyzed using the proposed pairwise pooling strategy. Batches used for the validation and test runs are described in Table 1 .
Concordance and sensitivity analysis in validation runs
The equivalence between the classical and the new proposed method was tested in two independent experiments with two validation LV batches spiked with one TCID50 of a RCL. For each run and each MOI tested, 16 flasks were transduced. The equivalence of both methods was confirmed by the full concordance of flask positivity/negativity in the two validation runs based on p24 concentration at day 29 and the acceptance criteria (defined in the Materials and Methods section). The final p24 concentration at day 29 allowed a clear discrimination between positive and negative flasks as the concentration was more than 5 log higher in positive flasks independently of the vector, the MOI, and the method used (Fig. 3) . A few flasks presented a delay in the production of infectious particles independently of the vector and the MOI used (Fig. 3) . As expected from a binomial distribution and according to the definition of one TCID50, the proportion of positive flasks was not significantly different from 50% in all conditions tested (IC95-binom (n=16, p=0.5) between 4 and 12). For the first validation batch tested, 7 and 5 out of 16 flasks were negative at, respectively, MOI 10 and 20 with both methods. Moreover, the same flask numbers were identified as positive or negative with both methods at each MOI. For the second vector tested, 7 and 12 out of 16 flasks were negative at, respectively, MOI 10 and 20 with both methods. As previously found, concordance of results at MOI 10 and 20 with both methods was 100%, confirming the equivalence of both methods for end-point analysis.
We noticed that the p24 concentrations reached by cells transduced with the vector and the positive control were slightly higher by the end of the assay at day 29 with the simulated-pooling strategy than with the standard method (Fig. 4A) . This observation probably reflects conditions for a more productive infection as fresh cells introduced from the reactor compartment or from other flasks at each passage can then be transduced by replicative particles produced during the previous passages and then continue to amplify the virus without inducing cell death. In contrast, the classical method maintains the replicative particle among the same population of cells that are only diluted with fresh medium and may experience some cytotoxicity and cell death by the end of the assay because of overinfection. The highest p24 concentration obtained by day 29 in the pooling arm indicated that pair-wise dilution caused no loss of sensitivity. To avoid false-negative results it is important to allow the amplification of any potential RCL during the early phase of the infection in a high-cell-density environment, and therefore pooling of flasks should not start before passage 2 (day 11). The exponential production of viral particles during this initial replication phase reduces the likelihood of failing to detect an RCL, even when parent flasks are pooled. Indeed, in a worst-case scenario in which each infected cell can only produce one replicative and infectious particle during its cell cycle, we Simulation of an RCL assay with a pairwise pooling strategy. In order to compare the standard method with the pooling method, we designed a simulated pooling assay. Sixteen flasks were seeded and transduced with the vector to test at MOI 10 or 20 together with one TCID50 of a positive control, leading to a theoretical 0.5 probability for each flask to be positive for the replicative virus. After a first passage at day 8 (P1), 5 and 10 ml of each flask was transferred to 2 new flasks, respectively, complemented with 5 ml of cells transduced with the same vector at the same MOI but without replicating virus (blue flask side culture reactor) and 30 ml fresh medium (lower part of the figure) or 30 ml fresh medium only (upper part of the figure) at passage 2. This dilution strategy was continued until P6, where 10 ml of cell suspension was transferred to 30 ml of fresh medium until final harvest for both methods. Indicator cells from the side culture reactor (blue flask) were transduced with the same vector but no replication-competent virus and routinely cultured during the whole duration of the experiment. Using this approach, each initial flask was analyzed by both methods in parallel for end-point positivity/negativity concordance analysis. TCID, tissue culture infective dose. number of infected cells in flask), wherein each draw is either a success or a failure. The kinetic of p24 decay was very similar between both methods but also between both validation batches carrying different transgenes. Control flasks from two additional and distinct test batches confirmed that the sensitivity of the new RCLpooling assay was not influenced by the vector/ transgene tested (Fig. 4B) . In both the validation runs (standard and simulated-pooling methods) and the two additional runs using the pooling method, untransduced cells did not show any detectable p24 during the whole duration of the assay, whereas the positive control (10TCID50) showed a clear increase in p24 concentration at passage P2 (day 11), indicating the presence of actively replicating viral particles. Hence, the sensitivity of the pooling method was very similar to the standard method because the initial replication phase of infectious particles was detected at the same time point in the two experimental approaches.
Independently of the batch, of the MOI and of the transgene, a gradual decrease of p24 concentrations was observed in cultures transduced with only the test vector, as expected from the successive dilutions and indicating no evidence of actively replicative particles (Fig. 4A) . The p24 concentration finally dropped below the limit of detection from day 22 to final harvest (P5, P6, and Harvest). Interestingly, the twofold difference in p24 concentrations between MOI 10 and MOI 20 conditions was maintained until day 29.
Cells transduced with 10 TCID50 of positive control together with an MOI 10 or 20 of test vector showed an early kinetic of p24 concentrations almost similar to cells transduced with the vector only until day 11 (P3) regardless of the MOI or the method used. From this time point on, p24 kinetics were similar to those of cells only transduced with the positive control, reaching the positivity threshold by day 22 (P5). The difference in p24 abundance between both MOI was maintained over the whole duration of the experiment with both methods confirming their equivalent sensitivity.
As a possible solution to decreasing material handling during the RCL assay, higher MOIs of chromatography-purified vectors were tested (10 and 20) even though high MOIs of rHIV-1 LV have been described to potentially induce more C8166-45 indicator cell toxicity, and inhibition of cell growth. 21 High MOIs may also reduce the RCL infection by competing for cell entry, and prolong the carryover of p24 proteins in the assay. In this context, the use of high MOIs could lead to a decrease in the RCL assay sensitivity. From our results, using MOIs 10 and 20 instead of the usual MOI 5, we observed that the use of high MOIs of test vector had no major impact on the detection of one TCID of positive control with both standard and RCL-pooling methods (Fig. 4A) . Furthermore, cell viability was not impaired by transduction at MOI 20, corresponding to 360 ng/ml of p24 proteins (Fig. 5A) , a concentration far below the recommended maximum concentration of 1000 ng/ ml. 21 A transient decrease of cell viability was ob- served during the amplification phase, but cell viability did not drop below 70% and rapidly normalized to 95% independently of the MOI. Moreover, untransduced and transduced cells at both MOIs, with all vector batches tested, had similar cell proliferation profiles, indicating the absence of major cytotoxic effect or growth inhibition because of high-transduction MOIs (Fig. 5B) . Even though we did not observe any toxicity with the tested vectors in this study, we recommend evaluating on a case-by-case basis the vector toxicity on indicator cells before proceeding to such a high MOI, especially if the viral purification method was not optimized and standardized. Increasing MOI may then be restricted to highly purified clinical-grade vectors.
RCL analysis in two clinical size test batches
After the validation runs, RCL testing was performed on two large-scale batches destined for clinical use at MOI 20 using the RCL pooling method (Fig. 1) . Starting from 38 and 52 flasks, using test batch 3 and 4, respectively (Table 1) , the final flask count was reduced to only 2 flasks by day 29. p24 proteins were undetectable in the remaining flasks, indicating that no RCL was present in the tested volume of both batches.
We also investigated the presence of specific sequences in those two vector batches, including the VSVg envelope gene, the HIV-1 GAG sequence (wtGAG), and the mutated GAG sequence (dGAG) from the transfer plasmid. The detection was performed at different time points in untransduced cells, cells infected with the positive control virus, and cells transduced with the two test batches. The VSVg sequence remained undetectable in all tested flasks (data not shown). The wtGAG sequence was increasingly detected in the positive control flask over time (300 copies per cells at day 29), highlighting the high permissivity of C8166-45 cells, whereas it was undetectable in cells transduced with the 2 test batches, confirming the absence of replicative viral particles in these latters (Fig. 6) . Conversely, dGAG sequence was detected at the end of the amplification phase (day 8, six copies per cell) in flask transduced with the tested vector and was progressively reduced to 3 copies per cell by the end of the study, confirming that cells were efficiently transduced by the test vectors. The detection of those specific sequences did not seem to be affected by the serial pairwise pooling strategy proposed.
Altogether, the results presented here indicate that the RCL-pooling method is as sensitive as the classical method to detect RCL in LV vector batches. This is confirmed for the two validation vectors tested and also independently of the MOI used (10 or 20) . This is the first time that a pairwise pooling strategy is implemented in the context of an RCL assay. This reduces the quantity of material to handle at advanced time points of the protocol. The estimated gain in material handling and operator manipulation time is close to 30%, even if the whole assay duration is maintained to a minimum of 29 days to allow full amplification of a potential RCL. This optimized cell-based assay should also be accompanied by specific sequences detection by PCR and PERT assays that are under validation.
This practical improvement in RCL testing that we report here can probably be further ameliorated. Indeed, pooling more than 2 flasks could be a reasonable option after the second passage of the assay because almost 10 5 TCID50 equivalents are detected 11 days posttransduction in the positive control condition. In conclusion, implementation of this pooling strategy in RCL testing should facili- tate testing of vector production scales that are continuously increasing (e.g., from 50-to 200-liter bioreactor productions) without compromising the sensitivity of the assay and yet providing real advantages in terms of material handling, operator time, and safety as well as cost effectiveness.
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